{"id":"W2240443346","doi":"10.1200/jco.2015.33.7_suppl.279","title":"IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Clinical endpoint; Prostate cancer; Internal medicine; Nausea; Prednisone; Adverse effect; Phases of clinical research; Progressive disease; Oncology; Gastroenterology; Chemotherapy; Cancer; Urology; Androgen deprivation therapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002260108,0.002022086,0.002290557,0.0009257244,0.0005795054,0.001111263,0.001545659,0.001668396,0.006045252],"category_scores_gemma":[0.001034273,0.001013827,0.001583824,0.0007817653,0.001308601,0.0009910506,0.0005301954,0.00433173,0.001800452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008213913,"about_ca_system_score_gemma":0.002627247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001434468,"about_ca_topic_score_gemma":0.00312145,"domain_scores_codex":[0.9994348,0.000294029,0.00002822612,0.00007262579,0.00004958277,0.0001207486],"domain_scores_gemma":[0.9991782,0.0001249507,0.0001026189,0.00007408144,0.00004243389,0.000477681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6756476,0.1895736,0.004699795,0.001195653,0.001080862,0.0005615367,0.0004360259,0.003008483,0.03475829,0.0003718447,0.003821098,0.08484519],"study_design_scores_gemma":[0.531234,0.4606167,0.004023687,0.00002088866,0.0001985319,0.0002586357,0.0000413039,0.0006356515,0.00154307,0.00008951873,0.001317379,0.00002072338],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878057,0.001619181,0.0008188828,0.0005609973,0.0002166754,0.005221849,0.001297543,0.000174737,0.00228441],"genre_scores_gemma":[0.9801618,0.002007458,0.002981555,0.001172826,0.0003305431,0.005184909,0.003348539,0.00004666687,0.004765689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006045252,"threshold_uncertainty_score":0.02022338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1486020752310335,"score_gpt":0.4968250447685502,"score_spread":0.3482229695375167,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}